Lbh 589 panobinostat

Ascorbic acid, β-glycerophosphate, dimethylsulfoxide (DMSO), AMD3100, SDF-1, and the protease inhibitor cocktail, were acquired from Sigma (St. Louis, MO, USA). SDF-1 was obtained from R&D Systems (Minneapolis, MN, USA). APC-conjugated annexin-V was purchased from BD Biosciences (San Jose, CA, USA). Suberoylanilide hydroxamic acid (SAHA, vorinostat) was procured from the Cancer Therapy Evaluation Program, National Cancer Institute (Bethesda, MD, USA). LBH-589 (panobinostat) was obtained from Selleckchem (Houston, TX, USA). CSA and TNAP inhibitor MLS-0038949 were purchased from Millipore (Burlington, MA, USA). Live/dead viability assays were obtained from Invitrogen (Waltham, MA, USA). The ON-TARGET Plus Control siRNA pool was purchased from GE Healthcare (Dharmacon) (Lafayette, CO, USA). The Alpl Silencer Select siRNA (ID: s62206) was purchased from Thermo Fisher Scientific (Ambion) (Waltham, MA, USA). Alpl (TNAP) mouse reactive polyclonal goat IgG antibody (AF2910) was purchased from R&D Systems (Minneapolis, MN, USA), and ERK 2 rabbit polyclonal IgG antibody (sc-154) was purchased from Santa Cruz (Dallas, Texas, USA).